Home › Rosetta Genomics, Meir Medical Partner on microRNA Biomarker Study

Rosetta Genomics, Meir Medical Partner on microRNA Biomarker Study

May 23, 2017

NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has partnered with Israel's Meir Medical Center to develop a microRNA-based test to identify non-small cell lung cancer (NSCLC) patients who would benefit from a specific class of immunotherapeutics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Molecular Diagnostics

  1. Roche Patent Invalidation Affirmed in TB Testing Lawsuit Against Cepheid

  2. Liquid Biopsy IDs More NSCLC Mutations, Yields Patient Therapy Response in Study of Guardant Test

  3. Sanofi Genzyme, PerkinElmer Launch Free Dx Program for Patients With Lysosomal Storage Disorders

  4. NanoString Announces $100 Million Term Loan Facility With CR Group

  5. Antibiotic Resistance Monitoring Consortium Expands to Highlight Battle Against Superbugs

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.